88768-40-5
Chemical Structure
Cilazapril
Synonym(s): Ro 31-2848
- CAS No.: 88768-40-5
- Formula:C22H31N3O5
- Molecular Weight:417.50
IUPAC Name: (1S,9S)-9-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)amino)-10-oxooctahydro-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid
InChIKey: HHHKFGXWKKUNCY-FHWLQOOXSA-N
SMILES: O=C([C@@H]1CCCN2N1C([C@@H](N[C@@H](CCC3=CC=CC=C3)C(OCC)=O)CCC2)=O)O
Biological Activity: Cilazapril is an orally active prodrug of the angiotensin-converting enzyme (ACE) inhibitor Cilazaprilat (HY-A0113). Cilazapril reduces plasma ACE activity. Cilazapril can be used in the research of hypertension (including essential and renal hypertension) and congestive heart failure[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Cilazapril | Cilazapril is an orally active prodrug of the angiotensin-converting enzyme (ACE) inhibitor Cilazaprilat (HY-A0113). Cilazapril reduces plasma ACE activity. Cilazapril can be used in the research of hypertension (including essential and renal hypertension) and congestive heart failure. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Cilazapril (Standard) | ≥98% | Cilazapril (Standard) is the analytical standard of Cilazapril (HY-A0043). This product is intended for research and analytical applications. Cilazapril is an orally active prodrug of the angiotensin-converting enzyme (ACE) inhibitor Cilazaprilat (HY-A0113). Cilazapril reduces plasma ACE activity. Cilazapril can be used in the research of hypertension (including essential and renal hypertension) and congestive heart failure. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Waterfall JF. A review of the preclinical cardiovascular pharmacology of cilazapril, a new angiotensin converting enzyme inhibitor. Br J Clin Pharmacol. 1989;27 Suppl 2(Suppl 2):139S-150S. [Content Brief]
- [2]. Asahi T, et al. Cilazapril prevents cardiac hypertrophy and postischemic myocardial dysfunction in hyperthyroid rats. Thyroid. 2001 Nov;11(11):1009-15. [Content Brief]
- [3]. Bhutto IA, et al. Effects of cilazapril on the retinal vessels in spontaneously hypertensive rats: corrosion cast and scanning electron microscopic study. Life Sci. 1999;64(3):PL27-39. [Content Brief]
- [4]. Szucs, T., Cilazapril. A review. Drugs, 1991. 41 Suppl 1: p. 18-24. [Content Brief]
- [5]. Nussberger, J., et al., Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. J Cardiovasc Pharmacol, 1987. 9(1): p. 39-44. [Content Brief]
